Viral Conjunctivitis - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Viral Conjunctivitis - Pipeline Review, H1 2019’, provides an overview of the Viral Conjunctivitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Viral Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis

- The report reviews pipeline therapeutics for Viral Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Viral Conjunctivitis therapeutics and enlists all their major and minor projects

- The report assesses Viral Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Viral Conjunctivitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Viral Conjunctivitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Viral Conjunctivitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adenovir Pharma AB

NanoViricides Inc

Panoptes Pharma GesmbH

Starpharma Holdings Ltd

Takeda Pharmaceutical Co Ltd

Adenovir Pharma AB

NanoViricides Inc

Panoptes Pharma GesmbH

Starpharma Holdings Ltd

Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Viral Conjunctivitis – Overview

Viral Conjunctivitis – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Viral Conjunctivitis – Overview

Viral Conjunctivitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Viral Conjunctivitis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Viral Conjunctivitis – Companies Involved in Therapeutics Development

Adenovir Pharma AB

NanoViricides Inc

Panoptes Pharma GesmbH

Starpharma Holdings Ltd

Takeda Pharmaceutical Co Ltd

Viral Conjunctivitis – Drug Profiles

APD-209 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APD-514 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

astodrimer – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EKCCide-I – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-102 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

povidone iodine ER – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranpirnase – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHP-640 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Viral Conjunctivitis – Dormant Projects

Viral Conjunctivitis – Discontinued Products

Viral Conjunctivitis – Product Development Milestones

Featured News & Press Releases

Dec 27, 2018: US FDA requests further data for VivaGel BV approval

Dec 12, 2018: US patent granted for SPL7013 eye drops for conjunctivitis

May 13, 2013: Starpharma's Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment

Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis

Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis

May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Viral Conjunctivitis, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development ...

List of Tables

Number of Products under Development for Viral Conjunctivitis, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Viral Conjunctivitis – Pipeline by Adenovir Pharma AB, H1 2019

Viral Conjunctivitis – Pipeline by NanoViricides Inc, H1 2019

Viral Conjunctivitis – Pipeline by Panoptes Pharma GesmbH, H1 2019

Viral Conjunctivitis – Pipeline by Starpharma Holdings Ltd, H1 2019

Viral Conjunctivitis – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019

Viral Conjunctivitis – Dormant Projects, H1 2019

Viral Conjunctivitis – Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Viral Conjunctivitis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Figures

Number of Products under Development for Viral Conjunctivitis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports